United States CAR-T Cell
Therapy Market is expected to grow at an impressive rate during the forecast
period, 2024-2028. The major factors include rising prevalence
of cancer consisting of myeloma, lymphoma,
leukemia, etc., rapidly expanding clinical trial activities, rise in awareness of CAR T
cell therapy, and recent commercialization of CAR-T cell therapy.
CAR-T (Chimeric Antigen
Receptor T-cell) therapy is an innovative type of immunotherapy that involves
genetically modifying a patient's own T- cells to recognize and attack cancer
cells. This therapy has shown remarkable results in the treatment of certain
types of blood cancer, such as acute lymphoblastic leukemia (ALL) and diffuse
large B-cell lymphoma (DLBCL). According to Leukemia and Lymphoma Society,
in 2021, an estimated 34,920 new cases of myeloma (19,320 males and 15,600
females) were expected to be diagnosed in the United States (U.S.), and an
estimated 138,415 people are living with myeloma in U.S. Additionally, in 2021,
61,090 people were expected to be diagnosed with leukemia in the U.S., and an
estimated 397,501 people are living with leukemia in the U.S.
The
Chimeric Antigen Receptor (CAR) T-cell therapy is for the treatment of
hematologic malignancies i.e., the cancers that begin in blood-forming tissue,
such as the bone marrow, or in the cells of the immune system like leukemia, lymphoma,
and multiple myeloma, etc. Another factor driving the market growth is the
increasing demand for personalized and targeted cancer therapies. CAR-T cell
therapy is a highly personalized treatment that involves modifying the patient's
immune cells to target cancer cells, making it a more effective and precise
treatment option for certain types of cancers.
According
to Global Cancer Observatory, in 2020, around 1 0,55,117 new
cancer cases were reported in United States of America. Moreover, the other factor includes the increasing
investments on healthcare sector, major involvement of market players, and increase in number of funding
activities. Various initiatives and awareness programs are taken by government
or private organization to raise awareness about diseases and treatments, and information about the availability of more
advanced technologies and procedures at healthcare facilities.
Rising Prevalence
of Cancer
In United States, cancer is the leading
cause of death. This is due to the physical carcinogens, such as ultraviolet
and ionizing radiation, chemical carcinogens, such as asbestos, components of
tobacco smoke, alcohol, aflatoxin (a food contaminant), and arsenic (a drinking
water contaminant) and biological carcinogens, such as infections from certain
viruses, bacteria, or parasites, and unhealthy lifestyle. According to American
Cancer Society, more than 1.8 million people were diagnosed with cancer in
2020. For instance, an estimated
1,519,907 people in the United States are suffering with leukemia, lymphoma,
myeloma, myelodysplastic syndromes (MDS) or myeloproliferative neoplasms (MPNs).
Therefore, the CAR-T Cell therapy enables the T cells to target cell surface
antigen for getting management and treatment for cancer. Thereby, it is
expected to drive the growth of the CAR-T Cell Therapy Market in United
States.
Recent Developments
In
2017, the first two autologous CAR T-cell therapies were approved by the US
Food and Drug Administration namely tisagenlecleucel (Kymriah) for the
treatment of patients up to 25 years of age with large B-cell lymphoma (refractory
or in second or later relapse), and axicabtagene ciloleucel (Yescarta), for the treatment of adults with large B-cell lymphoma (LBCL)
who either did not respond to first-line standard chemotherapy or relapsed
within 12 months of chemotherapy .
In
2020, the FDA had given the approval for brexucabtagene autoleucel (TecartusTM)
or the treatment of adults with r/r MCL and adult patients with relapsed or
refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Additionally,
in 2021, the FDA had given the approval for Lisocabtagene maraleucel (Breyanzi) or the treatment of adult patients with relapsed or
refractory large B-cell lymphoma after two or more lines of systemic therapy
and idecabtagene vicleucel (Abecma) for the treatment of adult patients with
relapsed or refractory multiple myeloma after four or more prior lines of
therapy.
Recently,
in March 2022, Ciltacabtagene autoleucel (CarvyktiTM) were approved by FDA for
the treatment of adult patients with relapsed or refractory multiple myeloma
who have already tried four or more prior lines of therapy.
Commercialization
of CAR-T Cell Therapy
The
commercialization of CAR-T Cell Therapy is the key challenge resulting in
restricting the growth of the market in the forecast period. This is due to the
complex manufacturing and supply chain, high-touch commercial model, and reimbursement
cost. All CAR T-cell therapies are autologous,
resulting in complex, costly manufacturing and supply chains. For instance, in
the United States, a limited number of certified academic medical centers
(AMCs) offers commercial CAR T, often requiring patients to travel long
distances to receive care. This is due to the limited number of commercial
sites which involves extensive preparation and
certification to offer CAR T therapies.
Increasing
Investments in Research and Development & Favorable Regulatory Environment
Research
and development are crucial for the advancement of CAR-T cell therapy. The
United States has a significant advantage in this regard, as it is home to some
of the world's leading research institutions and pharmaceutical companies.
These companies are investing heavily in CAR-T cell therapy research, which is
driving the market's growth. Additionally, the FDA discovered an improved
environment to give approval of two CAR-T cell therapies for use in the United
States, which has provided a boost to the market. The regulatory environment
for CAR-T cell therapy is favorable, which has encouraged more companies to
invest in this area. The FDA's expedited review process for breakthrough
therapies has helped speed up the approval process for CAR-T cell therapies,
which has contributed to market growth.
Download Free Sample Report
Market
Segmentation
The United
States CAR-T Cell Therapy Market can be segmented into product
type,
tumor type, indication, treatment type, targeted antigen, end user, and region. By product type, the market can be
segmented into Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel),
Tecartus (Brexucabtagene Autoleucel), Breyanzi (Lisocabtagene Maraleucel),
Abecma (Idecabtagene Vicleucel), and others. Based on tumor type, the market
can be segmented into Hematological Malignancies, and Solid Tumors. Based on
indication, the market can be segmented into Diffused Large B-Cell Lymphoma
(DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle
Cell Lymphoma (MCL), and Others. Based on treatment type, the market can be
segmented into Single Treatment and Combination Treatment. Based on targeted
antigen, the market can be segmented into CD 19, BCMA (B-Cell Maturation
Antigen), and Others. Based on end user, the market can be segmented into
Hospitals, Specialty Clinics, Ambulatory Surgical Centers, and Others.
Market Players
Gilead Sciences, Inc (US), Novartis
United States, AbbVie Inc., Myriad Genetics, NeoGenomics Laboratories, Intellia
Therapeutics (US), Agilent Technologies, Inc. (US), Abcam plc., Bio-Techne.
(ExoDx), Sangamo Therapeutics, Inc. (US) etc. are some of the leading companies operating in the market.
|
Attribute
|
Details
|
|
Base Year
|
2022
|
|
Historic Data
|
2018 – 2022
|
|
Estimated Year
|
2023
|
|
Forecast Period
|
2024 – 2028
|
|
Quantitative Units
|
Revenue in USD
Million, Volume Units and CAGR for 2018-2022 and 2023-2028
|
|
Report coverage
|
Revenue forecast, Volume
forecast company share, competitive landscape, growth factors, and trends
|
|
Segments covered
|
Product Type
Tumor Type
Indication
Treatment Type
Targeted
Antigen
End User
Region
Company
|
|
Regional scope
|
Northeast Region, Midwest Region, South
Region, West Region
|
|
Key companies profiled
|
Gilead
Sciences, Inc (US), Novartis United States, AbbVie Inc., Myriad Genetics,
NeoGenomics Laboratories, Intellia Therapeutics (US), Agilent Technologies,
Inc. (US), Abcam plc., Bio-Techne. (ExoDx), Sangamo Therapeutics, Inc. (US).
|
|
Customization scope
|
10% free report customization with purchase. Addition or
alteration to country, regional & segment scope.
|
|
Pricing and purchase options
|
Avail customized purchase options to meet your exact research
needs. Explore purchase options
|
|
Delivery Format
|
PDF and Excel through Email (We can also
provide the editable version of the report in PPT/Word format on special
request)
|
Report Scope:
In this report, United States CAR-T Cell
Therapy Market has been segmented into following categories, in addition to the
industry trends which have also been detailed below:
·
United States CAR-T Cell Therapy Market, By Product Type
o Yescarta (Axicabtagene Ciloleucel)
o Kymriah (Tisagenlecleucel)
o Tecartus (Brexucabtagene Autoleucel)
o Breyanzi (Lisocabtagene Maraleucel)
o Abecma (Idecabtagene Vicleucel)
o Others
·
United
States CAR-T Cell Therapy Market, Tumor Type
o Hematological Malignancies
o Solid Tumors
·
United
States CAR-T Cell Therapy Market, By Indication
o
Diffused
Large B-Cell Lymphoma (DLBCL)
o
Acute
Lymphoblastic Leukemia (ALL)
o
Follicular
Lymphoma (FL)
o
Mantle
Cell Lymphoma (MCL)
o
Others
·
United
States CAR-T Cell Therapy Market, By Treatment Type
o Single Treatment
o Combination Treatment
·
United
States CAR-T Cell Therapy Market, By Targeted Antigen
o CD 19
o BCMA (B-Cell Maturation Antigen)
o Others
·
United
States CAR-T Cell Therapy Market, By End User
o
Hospitals
o
Specialty
Clinics
o
Ambulatory
Surgical Centers
o
Others
·
United States CAR-T Cell
Therapy Market, By Region:
o
Northeast
o
Midwest
o
South
o
West
Competitive Landscape
Company Profiles: Detailed analysis of the major
companies present in United States CAR-T Cell Therapy Market
Available Customizations:
With the given market data, TechSci Research offers
customizations according to a company’s specific needs. The following customization
options are available for the report:
Company
Information:
- Detailed analysis and profiling of additional market players (up to five).
United States CAR-T Cell Therapy Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]